No association of adiponectin +45 T/G polymorphism with the risk of gestational diabetes mellitus: Evidence from a meta-analysis.

INTRODUCTION

Adiponectin (ADIPOQ), involved in regulating glucose levels and fatty acid oxidation, plays key roles in metabolic derangements such as gestational diabetes mellitus (GDM). Previously, several studies have been conducted to assess the association between ADIPOQ +45 T/G polymorphism and risk of GDM. The results, however, are inconclusive. We aimed to evaluate the effect of the polymorphism on the risk of GDM using a meta-analysis.

MATERIALS AND METHODS

After databases searching, eight records were identified. Pooled odds ratios (ORs) with their corresponding 95% confidence intervals (CIs) were used to evaluate the association between ADIPOQ +45 T/G polymorphism and risk of GDM.

RESULTS

No significant association was observed between the ADIPOQ +45 T/G polymorphism and the risk of GDM (heterozygote comparison: OR = 1.15, 95% CI, 0.70-1.89; homozygote comparison: OR = 1.21, 95% CI, 0.48-3.03; dominant model: OR = 0.86, 95% CI, 0.50-1.48, recessive model: OR = 1.21, 95% CI, 0.62-2.33, and allele comparison: OR = 1.17, 95% CI, 0.79-1.76, respectively). Apparent heterogeneity was detected. However, no evidence of publication bias was found.

CONCLUSIONS

This meta-analysis provides evidence that the ADIPOQ +45 T/G polymorphism was not related to the risk of GDM. Further multicenter, prospective studies with larger sample size would be valuable to confirm the result.